TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6680021

Group type: EXPERIMENTAL
Intervention: Cyclical levamisole treatment (150 mg daily for 3 days repeated after a gap of 2 weeks) in addition to standard DDS treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard DDS treatment and placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cyclical levamisole treatment
Number of subjects: 15
Study: 31662536

Group type: EXPERIMENTAL
Intervention: Continuation of platinum agents (PTs)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Discontinuation of platinum agents (PTs) or switching to non-platinum agents
Number of subjects: 31
Study: 30239425

Group type: EXPERIMENTAL
Intervention: Dispersible FDC tablet of abacavir 150 mg/dolutegravir 10 mg/lamivudine 75 mg administered in high- or zero-mineral content water, either immediately or after a 30-minute delay.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondispersible dolutegravir 10 mg tablets plus nondispersible abacavir 600 mg/lamivudine 300 mg tablet administered with zero-mineral content water.
Number of subjects: 0
Study: 27426855

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 75 mg and heparin 5000 IU subcutaneous every 12 h
Number of subjects: 180

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin and heparin
Number of subjects: 180
Study: 24299019

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus omega-3 fatty acid ethyl esters (4 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22326818

Group type: EXPERIMENTAL
Intervention: Counselling intervention addressing workplace barriers and physical activity
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 110
Study: 21157172

Group type: EXPERIMENTAL
Intervention: Aromatherapy with a blend of oils (lemon, lavender, ylang ylang)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with artificial lemon fragrance (Limonene and Citral)
Number of subjects: 42
Study: 17823519

Group type: EXPERIMENTAL
Intervention: Daivobet/Dovobet/Taclonex (calcipotriol/betamethasone) once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-fix calcipotriol/betamethasone combination (morning/evening)
Number of subjects: 0
Study: 16158081

Group type: COMPARATOR
Intervention: High-Fat (HF) diet
Number of subjects: 93

Group type: COMPARATOR
Intervention: High-Protein (HP) diet
Number of subjects: 93

Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 93
Study: 15454358

Group type: EXPERIMENTAL
Intervention: African dance
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 69

Group type: COMPARATOR
Intervention: Biology lecture (Control)
Number of subjects: 69
Study: 10806134

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 40
Study: 8965138

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled modified recombinant tissue plasminogen activator (rt-PA) scintigraphy
Number of subjects: 79
Study: 1376197

Group type: EXPERIMENTAL
Intervention: Operative and nonoperative treatment options based on prostate size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive video disc for explaining treatment options
Number of subjects: 0
Study: 3975120

Group type: EXPERIMENTAL
Intervention: High-dose phototherapy (12 microW/cm2/nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-dose phototherapy (6 microW/cm2/nm)
Number of subjects: 20
Study: 30920174

Group type: EXPERIMENTAL
Intervention: Exercise + ginseng supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 12
Study: 27312207

Group type: EXPERIMENTAL
Intervention: Low fluidic settings
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard fluidic settings
Number of subjects: 43
Study: 25673450

Group type: EXPERIMENTAL
Intervention: Closed reduction and internal fixation (Group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Capsulotomy and internal fixation with iliac bone grafting (Group B)
Number of subjects: 65
Study: 23279372

Group type: EXPERIMENTAL
Intervention: sCD30 concentration ≥40.3 U/ml on day 14
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: anti-HLA class II reactivities with a cut-off value of 140 optical density
Number of subjects: 28

Group type: COMPARATOR
Intervention: Withdrawal of steroids
Number of subjects: 28
Study: 21995804

Group type: EXPERIMENTAL
Intervention: Paramedic cooling during CPR using rapid infusion of ice-cold normal saline (4 °C, 20-40 mL/kg to a maximum of 2 litres)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment during CPR
Number of subjects: 0
Study: 18812677

Group type: EXPERIMENTAL
Intervention: Low-dose carperitide (0.01-0.05 microg x kg(‐1 ) x min(‐1)) for 72 hours
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard medical treatment (control group)
Number of subjects: 49
Study: 16860048

Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception (2 x 0.75 mg levonorgestrel pills - Plan B)
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Information only (identical packet containing EC information)
Number of subjects: 9000
Study: 12632130

Group type: EXPERIMENTAL
Intervention: 10 mmHg insufflation pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: 15 mmHg insufflation pressure
Number of subjects: 30
Study: 10988110

Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg intravenously every 3 months) with vitamin D (800 IU/d) and calcium (1 g/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vitamin D (800 IU/d) and calcium (1 g/d) alone (Control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 8792783

Group type: EXPERIMENTAL
Intervention: Targeted Intervention (TI) group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 301
Study: 1291309

Group type: EXPERIMENTAL
Intervention: Clindamycin 150 mg every 6 h for seven days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin 1 g every 12 h for seven days
Number of subjects: 60
Study: 6379870

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 31288792

Group type: EXPERIMENTAL
Intervention: Home-based education intervention led by Community Health Workers (CHWs) referencing the Asthma and Healthy Homes curriculum
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 290
Study: 28055000

Group type: EXPERIMENTAL
Intervention: Consensus recommendations for tailored management of asthma based on attitudinal-control clusters.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pharmacological approaches (e.g., step‐up/down; self‐management; simplified regimen) and non‐pharmacological approaches (e.g., trigger management, education, social support; inhaler technique).
Number of subjects: 10
Study: 26948284

Group type: EXPERIMENTAL
Intervention: 49-mg p-synephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24709636

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 70
Study: 22804846

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) in caregivers
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) in people with PD
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Caregiver strain
Number of subjects: 97
Study: 18534395

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) navigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 60
Study: 17889355

Group type: EXPERIMENTAL
Intervention: Autologous GVHD induction arm (cyclosporine, interleukin-2, gamma-interferon)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Noninduction arm
Number of subjects: 51
Study: 14665611

Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin and infused fluorouracil plus leucovorin)
Number of subjects: 795

Group type: COMPARATOR
Intervention: IFL (irinotecan and bolus fluorouracil plus leucovorin)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: IROX (irinotecan and oxaliplatin)
Number of subjects: 795
Study: 12567513

Group type: EXPERIMENTAL
Intervention: 0.2% Brimonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% Carteolol
Number of subjects: 0
Study: 9431375

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir followed by oral acyclovir (10 mg/[kg.d] for 2 weeks, then 800 mg/m2 four times daily for 50 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous ganciclovir alone (10 mg/[kg.d] for 2 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir followed by oral acyclovir
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous ganciclovir alone
Number of subjects: 48
Study: 8327330

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 3014851

Group type: EXPERIMENTAL
Intervention: Suloctidil (200 mg 3 times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30755559

Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate (GTN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimetazidine (TMZ)
Number of subjects: 0
Study: 28541770

Group type: EXPERIMENTAL
Intervention: Breathing Control (BC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 27450153

Group type: EXPERIMENTAL
Intervention: snus
Number of subjects: 626
Study: 24373326

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin-C (MMC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Deep sclerectomy without mitomycin-C (non-MMC)
Number of subjects: 37
Study: 23010234

Group type: EXPERIMENTAL
Intervention: 3 years of HDM SIT (SIT3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5 years of HDM SIT (SIT5)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (parents refused HDM SIT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SIT5
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SIT3
Number of subjects: 90
Study: 19650801

Group type: EXPERIMENTAL
Intervention: RSI-controlled
Number of subjects: 30

Group type: COMPARATOR
Intervention: RSI-classic
Number of subjects: 30
Study: 17803670

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (STSC)
Number of subjects: 126
Study: 14712432

Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (6 times/week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 times/week)
Number of subjects: 21
Study: 11842483

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 0
Study: 10222711

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative follow-up
Number of subjects: 0
Study: 8821277

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 15
Study: 2167820

Group type: EXPERIMENTAL
Intervention: Aluminium citrate (Al‐cit) treatment group, injected with 120 mg Al/year for five years
Number of subjects: 917

Group type: COMPARATOR
Intervention: Control group, received a consolatant or nothing during the period of five years
Number of subjects: 917
Study: 7028636

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 3 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 10 days
Number of subjects: 43
Study: 30730958

Group type: EXPERIMENTAL
Intervention: Sportsmanlike and nonviolent profile
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Sportsmanlike and violent profile
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Unsportsmanlike and nonviolent profile
Number of subjects: 595
Study: 28545589

Group type: EXPERIMENTAL
Intervention: Low FODMAP ONS (formulas A, B, and C)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Positive control (5 g fructooligosaccharides mixed in lactose-free milk)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All treatments (including low FODMAP ONS and positive control)
Number of subjects: 21
Study: 26027629

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1106
Study: 23711745

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% fat) with >2 prot% increase
Number of subjects: 771

Group type: COMPARATOR
Intervention: High-fat diet (40-45% fat) with >2 prot% decrease
Number of subjects: 771
Study: 21895947

Group type: EXPERIMENTAL
Intervention: Supervised exercise and home exercise counselling (study group; n = 40)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine prenatal care programme (control group; n = 42)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supervised exercise (study group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine prenatal care programme (control group)
Number of subjects: 82
Study: 19640734

Group type: EXPERIMENTAL
Intervention: Local anesthetic agent (prilocaine 2%) plus 500 microg nitroglycerin (group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Local anesthetic agent (prilocaine 2%) (group B)
Number of subjects: 63
Study: 17366257

Group type: EXPERIMENTAL
Intervention: Teleconferencing Supervision during 5 counseling sessions
Number of subjects: 13
Study: 15662091

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/d)
Number of subjects: 63
Study: 11094579

Group type: COMPARATOR
Intervention: i.v. ondansetron 4 mg (control)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 4 mg and cyclizine 50 mg (combination)
Number of subjects: 139

Group type: COMPARATOR
Intervention: i.v. saline 0.9% (placebo)
Number of subjects: 139
Study: 8834689

Group type: EXPERIMENTAL
Intervention: 50% tilt
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 65% tilt
Number of subjects: 33

Group type: COMPARATOR
Intervention: 40% tilt
Number of subjects: 33
Study: 1422320

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 6362386

Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 3550214

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg 6 hr‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg day‐1) with prazosin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg day‐1) with prazosin and captopril (25 mg 6 hr‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Furosemide (40 mg day‐1) alone
Number of subjects: 6
Study: 28961803

Group type: EXPERIMENTAL
Intervention: PF‐00547659 22.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐00547659 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐00547659 225 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐00547659
Number of subjects: 0
Study: 26778925

Group type: EXPERIMENTAL
Intervention: High protein diet (>3 g/kg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal (habitual) diet (2.6 ± 0.8 g/kg/day)
Number of subjects: 12
Study: 25246821

Group type: EXPERIMENTAL
Intervention: Gadoxetic acid injection at 0.5 mL/s (n = 50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Gadoxetic acid injection at 1 mL/s (n = 51)
Number of subjects: 101
Study: 23810267

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention addressing individual needs related to asthma control, inhaler technique, and medication adherence
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 336
Study: 20971961

Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg IV over 30 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nefopam 20 mg IV over 30 minutes (healthy volunteers)
Number of subjects: 12
Study: 18311576

Group type: EXPERIMENTAL
Intervention: Annual physical examination, neck ultrasonography, and serum thyroid-stimulating hormone (TSH) measurement for patients undergoing thyroid lobectomy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual physical examination and serum TSH measurement for patients undergoing total thyroidectomy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine thyroxine and/or iodine supplementation for preventing recurrence in patients from iodine-deficient regions.
Number of subjects: 0
Study: 15765200

Group type: EXPERIMENTAL
Intervention: AQUANOVA solubilisate (100 IU alpha-tocopheryl acetate and 400 mg crystalline vitamin C) in the form of vitaminized gummi bears
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference products (conventional preparations)
Number of subjects: 14
Study: 14597524

Group type: EXPERIMENTAL
Intervention: 8.0 mm grafts
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: 7.5 mm grafts
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: 7.0 mm grafts
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: 7.0 mm grafts (all sutures out)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Keratometric astigmatism (KA)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Surface Regularity Index (SRI)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Surface Asymmetry Index (SAI)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Proportion of regular keratometry mires
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Proportion of not measurable keratometries
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: SRI (all sutures out)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: SAI (all sutures out)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Proportion of regular keratometry mires (all sutures out)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Proportion of not measurable keratometries (all sutures out)
Number of subjects: 797
Study: 10758988

Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 10:1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 16:1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 6:1
Number of subjects: 48
Study: 8703168

Group type: EXPERIMENTAL
Intervention: Enoxaparin (one month duration)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo (one month duration)
Number of subjects: 262
Study: 1578626

Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide (0.2 mg.kg-1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide (0.4 mg.kg-1)
Number of subjects: 42
Study: 4092801

Group type: EXPERIMENTAL
Intervention: 2.5% indomethacin solution applied 1 hour before UVB irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin applied before irradiation
Number of subjects: 0
Study: 29128649

Group type: EXPERIMENTAL
Intervention: Web‐version of Prolonged Exposure (Web‐PE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: In-person Present‐Centered Therapy (PCT)
Number of subjects: 120
Study: 27644242

Group type: EXPERIMENTAL
Intervention: ZinutriK® (4 weeks)
Number of subjects: 16
Study: 25005045

Group type: EXPERIMENTAL
Intervention: Ringerfundin® solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glucose/potassium‐based balanced crystalloid solution
Number of subjects: 44
Study: 23000038

Group type: EXPERIMENTAL
Intervention: MIPPO technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional open reduction
Number of subjects: 64
Study: 20797379

Group type: EXPERIMENTAL
Intervention: Higher number of previous episodes
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: More residual symptoms
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Lower levels of positive refocusing
Number of subjects: 172
Study: 19128589

Group type: EXPERIMENTAL
Intervention: Amikacin therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Caloric test
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: VEMPs
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68
Study: 15920378

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 24
Study: 12946545

Group type: EXPERIMENTAL
Intervention: Ketotifen ophthalmic solution (0.025%)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ketotifen with desloratadine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Desloratadine (5 mg tablets)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ketotifen ophthalmic solution
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combination treatment (ketotifen and desloratadine)
Number of subjects: 82
Study: 10644288

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once in the evening)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Salmeterol (50 microg [2 puffs] twice daily)
Number of subjects: 191
Study: 8738513

Group type: EXPERIMENTAL
Intervention: Prophylactic group (breast-fed with mothers excluding highly antigenic foods or given extensively hydrolysed formula)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prophylactic group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (fed conventionally by breast or formula, no specific environmental measures)
Number of subjects: 120
Study: 1362432

Group type: EXPERIMENTAL
Intervention: Somatostatin (continuous infusion of 250 micrograms/h for 5 days plus daily bolus administration of 250 micrograms)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 80
Study: 3922510

Group type: COMPARATOR
Intervention: Nicotine gum with no further appointments (Control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nicotine gum with four further appointments over three months (Intervention)
Number of subjects: 200